(KRYS) Krystal Biotech - Ratings and Ratios
VYJUVEK, Gene Therapies
KRYS EPS (Earnings per Share)
KRYS Revenue
Description: KRYS Krystal Biotech
Krystal Biotech Inc (NASDAQ:KRYS) is a commercial-stage biotechnology company focused on developing genetic medicines for diseases with high unmet medical needs. The company has a commercialized product, VYJUVEK (B-VEC), for treating dystrophic epidermolysis bullosa (DEB), a rare genetic disorder.
The companys pipeline includes several promising candidates: KB105 for treating autosomal recessive congenital ichthyosis, KB104 for Netherton syndrome, KB407 for cystic fibrosis, KB707 for anti-PD-1 relapsed/refractory cancers, KB408 for Alpha-1 antitrypsin deficiency, and KB301 for aesthetic skin conditions. Notably, several of these candidates are in clinical trials (Phase 1/2), indicating a robust development program.
From a financial perspective, KRYS has a market capitalization of approximately $4.27 billion, with a forward P/E ratio of 24.51, suggesting a relatively high growth expectation. The companys Return on Equity (RoE) is 13.56%, indicating a decent level of profitability. To further evaluate the companys performance, we can examine additional KPIs such as Revenue Growth Rate, Gross Margin, and Operating Cash Flow. A high Revenue Growth Rate would indicate successful commercialization of its products, while a stable Gross Margin would suggest effective cost management. A positive Operating Cash Flow would demonstrate the companys ability to generate cash from its operations.
To assess the stocks performance, we can look at its price action relative to its moving averages. With a current price above its 20-day and 50-day SMA, the stock is showing a short-term uptrend. However, being below its 200-day SMA may indicate a longer-term downtrend. Further analysis of the stocks volatility, as measured by ATR (4.68 = 3.06%), can provide insights into potential risks and opportunities.
KRYS Stock Overview
| Market Cap in USD | 4,159m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-09-20 |
KRYS Stock Ratings
| Growth Rating | 27.0% |
| Fundamental | 85.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -32.6% |
| Analyst Rating | 4.64 of 5 |
KRYS Dividends
Currently no dividends paidKRYS Growth Ratios
| Growth Correlation 3m | 32.7% |
| Growth Correlation 12m | -71.2% |
| Growth Correlation 5y | 88.5% |
| CAGR 5y | 31.41% |
| CAGR/Max DD 3y | 0.74 |
| CAGR/Mean DD 3y | 3.09 |
| Sharpe Ratio 12m | 0.22 |
| Alpha | -36.94 |
| Beta | 0.671 |
| Volatility | 47.03% |
| Current Volume | 754.1k |
| Average Volume 20d | 261.8k |
| Stop Loss | 149.9 (-3.7%) |
| Signal | 2.54 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (146.7m TTM) > 0 and > 6% of Revenue (6% = 21.6m TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA 27.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 210.0% (prev 367.5%; Δ -157.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 195.4m > Net Income 146.7m (YES >=105%, WARN >=100%) |
| Net Debt (-352.2m) to EBITDA (112.0m) ratio: -3.14 <= 3.0 (WARN <= 3.5) |
| Current Ratio 9.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.7m) change vs 12m ago 0.38% (target <= -2.0% for YES) |
| Gross Margin 93.37% (prev 90.97%; Δ 2.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 34.94% (prev 18.11%; Δ 16.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 3.61
| (A) 0.66 = (Total Current Assets 841.3m - Total Current Liabilities 86.9m) / Total Assets 1.14b |
| (B) -0.09 = Retained Earnings (Balance) -106.6m / Total Assets 1.14b |
| (C) 0.10 = EBIT TTM 107.3m / Avg Total Assets 1.03b |
| (D) -1.08 = Book Value of Equity -105.4m / Total Liabilities 97.7m |
| Total Rating: 3.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.83
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 5.32% = 2.66 |
| 3. FCF Margin 51.63% = 7.50 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda 0.11 = 2.49 |
| 6. ROIC - WACC 10.40% = 12.50 |
| 7. RoE 15.21% = 1.27 |
| 8. Rev. Trend 90.94% = 4.55 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 94.55% = 2.36 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of KRYS shares?
Over the past week, the price has changed by +7.24%, over one month by +3.62%, over three months by +17.04% and over the past year by -19.85%.
Is Krystal Biotech a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KRYS is around 166.63 USD . This means that KRYS is currently overvalued and has a potential downside of 7.01%.
Is KRYS a buy, sell or hold?
- Strong Buy: 8
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the KRYS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 205.2 | 31.8% |
| Analysts Target Price | 205.2 | 31.8% |
| ValueRay Target Price | 185.8 | 19.3% |
Last update: 2025-09-16 04:37
KRYS Fundamental Data Overview
CCE Cash And Equivalents = 682.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 29.2627
P/E Forward = 21.4592
P/S = 11.577
P/B = 3.9961
Beta = 0.654
Revenue TTM = 359.2m USD
EBIT TTM = 107.3m USD
EBITDA TTM = 112.0m USD
Long Term Debt = 10.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.62m USD (from shortTermDebt, last quarter)
Debt = 12.5m USD (Calculated: Short Term 1.62m + Long Term 10.9m)
Net Debt = -352.2m USD (from netDebt column, last quarter)
Enterprise Value = 3.49b USD (4.16b + Debt 12.5m - CCE 682.0m)
Interest Coverage Ratio = unknown (Ebit TTM 107.3m / Interest Expense TTM 0.0)
FCF Yield = 5.32% (FCF TTM 185.4m / Enterprise Value 3.49b)
FCF Margin = 51.63% (FCF TTM 185.4m / Revenue TTM 359.2m)
Net Margin = 40.85% (Net Income TTM 146.7m / Revenue TTM 359.2m)
Gross Margin = 93.37% ((Revenue TTM 359.2m - Cost of Revenue TTM 23.8m) / Revenue TTM)
Tobins Q-Ratio = -33.09 (set to none) (Enterprise Value 3.49b / Book Value Of Equity -105.4m)
Interest Expense / Debt = 200.5% (Interest Expense 25.0m / Debt 12.5m)
Taxrate = 6.50% (6.20m / 95.4m)
NOPAT = 100.3m (EBIT 107.3m * (1 - 6.50%))
Current Ratio = 9.68 (Total Current Assets 841.3m / Total Current Liabilities 86.9m)
Debt / Equity = 0.01 (Debt 12.5m / last Quarter total Stockholder Equity 1.04b)
Debt / EBITDA = 0.11 (Net Debt -352.2m / EBITDA 112.0m)
Debt / FCF = 0.07 (Debt 12.5m / FCF TTM 185.4m)
Total Stockholder Equity = 964.4m (last 4 quarters mean)
RoA = 12.89% (Net Income 146.7m, Total Assets 1.14b )
RoE = 15.21% (Net Income TTM 146.7m / Total Stockholder Equity 964.4m)
RoCE = 11.00% (Ebit 107.3m / (Equity 964.4m + L.T.Debt 10.9m))
RoIC = 10.40% (NOPAT 100.3m / Invested Capital 964.4m)
WACC = unknown (E(4.16b)/V(4.17b) * Re(8.49%)) + (D(12.5m)/V(4.17b) * Rd(none%) * (1-Tc(0.06)))
Shares Correlation 3-Years: 78.79 | Cagr: 1.37%
Discount Rate = 8.49% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 68.46% ; FCFE base≈185.4m ; Y1≈121.8m ; Y5≈55.7m
Fair Price DCF = 35.07 (DCF Value 1.02b / Shares Outstanding 28.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 94.55 | EPS CAGR: 0.0% | SUE: 0.19 | # QB: False
Revenue Correlation: 90.94 | Revenue CAGR: 0.0%
Additional Sources for KRYS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle